Inborn errors of purine and pyrimidine metabolism: A guide to diagnosis

被引:10
作者
Jurecka, Agnieszka [1 ,3 ]
Tylki-Szymanska, Anna [2 ]
机构
[1] CoA Therapeut, Palo Alto, CA USA
[2] Childrens Mem Hlth Inst, Warsaw, Poland
[3] 1800 Owens St,Suite C-1200, San Francisco, CA 94158 USA
关键词
Encephalopathy; Hypotonia; Myopathy; Purines; Pyrimidines; Seizures; ADENYLOSUCCINATE LYASE DEFICIENCY; MITOCHONDRIAL-DNA DEPLETION; BETA-UREIDOPROPIONASE DEFICIENCY; DOMINANT RETINITIS-PIGMENTOSA; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDINE KINASE; HPRT DEFICIENCY; DISORDERS; DEGRADATION; MUTATIONS;
D O I
10.1016/j.ymgme.2022.02.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inborn errors of purine and pyrimidine (P/P) metabolism are under-reported and rarely mentioned in the general literature or in clinical practice, as well as in reviews dedicated to other inborn errors of metabolism (IEMs). However, their diagnosis is important because genetic counseling can be provided and, in some cases, specific treatment exists that may slow or even reverse clinical signs. The purpose of this review is to provide a practical guideline on the suspicion and investigation of inborn errors of P/P metabolism. Failure of a physician to recognize the presence of these disorders may be devastating for affected infants and children because of its permanent effects in the patient, and for their parents because of implications for future offspring. Diagnosis is crucial because genetic counseling can be provided and, in some cases, specific treatment can be offered that may slow or even reverse clinical symptoms. This review highlights the risk factors in the history, the important examination findings, and the appropriate biochemical investigation of the child. Herein we describe the approach to the diagnosis of P/P disorders and emphasize clinical situations in which physicians should consider these diseases as diagnostic possibilities.
引用
收藏
页码:164 / 176
页数:13
相关论文
共 75 条
[71]   Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency [J].
Van Kuilenburg, ABP ;
Vreken, P ;
Abeling, NGGM ;
Bakker, HD ;
Meinsma, R ;
Van Lenthe, H ;
De Abreu, RA ;
Smeitink, JAM ;
Kayserili, H ;
Apak, MY ;
Christensen, E ;
Holopainen, I ;
Pulkki, K ;
Riva, D ;
Botteon, G ;
Holme, E ;
Tulinius, R ;
Kleijer, WJ ;
Beemer, FA ;
Duran, M ;
Niezen-Koning, KE ;
Smit, GPA ;
Jakobs, C ;
Smit, LME ;
Moog, U ;
Spaapen, LJM ;
Van Gennip, AH .
HUMAN GENETICS, 1999, 104 (01) :1-9
[72]  
van Kuilenburg ABP, 2000, CLIN CANCER RES, V6, P4705
[73]   Inborn errors of pyrimidine degradation: Clinical, biochemical and molecular aspects [J].
vanGennip, AH ;
Abeling, NGGM ;
Vreken, P ;
vanKuilenburg, ABP .
JOURNAL OF INHERITED METABOLIC DISEASE, 1997, 20 (02) :203-213
[74]   Screen of the IMPDH1 gene among patients with dominant retinitis pigmentosa and clinical features associated with the most common mutation, Asp226Asn [J].
Wada, Y ;
Sandberg, MA ;
McGee, TL ;
Stillberger, MA ;
Berson, EL ;
Dryja, TP .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (05) :1735-1741
[75]   A Patient With CAD Deficiency Responsive to Uridine and Literature Review [J].
Zhou, Ling ;
Xu, Han ;
Wang, Tianshuang ;
Wu, Ye .
FRONTIERS IN NEUROLOGY, 2020, 11